HLB Therapeutics Co.,Ltd. (KOSDAQ:115450)

HLB Therapeutics Revenue

HLB Therapeutics had revenue of 12.56B KRW in the quarter ending June 30, 2026, a decrease of -19.87%. This brings the company's total for the last twelve months to 64.45B, up 5.25% year-over-year. In the year 2025, HLB Therapeutics had annual revenue of 69.56B with 26.63% growth. That makes HLB Therapeutics the 28,237th largest company in the world by revenue and 1,714th in South Korea.

• Revenue (ttm): 64.45B
• Revenue Growth: +5.25%
• P/S Ratio: 3.41
• Revenue / Employee: 1.32B
• Employees: 49
• Market Cap: 242.82B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Cold Chain Business 58.82B 79.3%
• Electronics Business 10.75B 14.5%
• Headquarters and Bio Business 4.57B 6.2%

By Geography

Chart

• South Korea 68.22B 98.1%
• Overseas 1.35B 1.9%

Fiscal year ended Dec 31, 2025 See the full HLB Therapeutics breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	69.56B	14.63B	26.63%
Dec 31, 2024	54.93B	2.34B	4.45%
Dec 31, 2023	52.59B	10.19B	24.03%
Dec 31, 2022	42.40B	-1.18B	-2.72%
Dec 31, 2021	43.59B	656.63M	1.53%

Data Source: S&P Global Market Intelligence Last updated: Aug 13, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 31, 2026

Data Sources Report a data error